Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,708,648 papers from all fields of science
Search
Sign In
Create Free Account
PNT2258
Known as:
DNA Interference Oligonucleotide PNT2258
A liposomal formulation of the 24-mer oligonucleotide PNT100, with potential antineoplastic activity. PNT2258 targets and complements to…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
PNT100
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Unintended target effect of anti-BCL-2 DNAi
A. Ebrahim
,
M. Kandouz
,
Nada Emara
,
Amara B Sugalski
,
L. Lipovich
,
A. Al-Katib
Cancer Management and Research
2017
Corpus ID: 29814906
Introduction Previous research suggested that a novel compound PNT2258 inhibits B-cell lymphoma 2 (BCL-2) transcription by DNA…
Expand
2016
2016
A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large b-cell lymphoma (DLBCL): An initial report from the Wolverine study.
J. Westin
,
M. Maris
,
+7 authors
B. Klencke
2016
Corpus ID: 81946253
TPS7577Background: PNT2258, a liposomal encapsulated DNA interference (DNAi) oligonucleotide nanoparticle targeting the BCL2…
Expand
2014
2014
Pharmacokinetics of the BCL2-targeted DNA interference (DNAi) nanoparticle PNT2258 in patients with recurrent or refractory non-Hodgkin lymphoma.
W. Harb
,
N. Lakhani
,
+8 authors
A. Al-Katib
2014
Corpus ID: 81874719
2586 Background: PNT2258 contains PNT100, a DNA interference (DNAi) oligonucleotide encapsulated in a lipid nanoparticle. PNT2258…
Expand
2013
2013
Abstract 3529: Effect of PNT2258, an anti-BCL2 DNA-interference drug, on tumor growth and immunological markers in mice and humans.
E. Izbicka
,
R. Streeper
,
+8 authors
W. Rodrigueza
2013
Corpus ID: 71507293
Background: The dysregulation of apoptosis is a defining characteristic of malignant cells where excessive concentration of BCL2…
Expand
2012
2012
Abstract 2764: Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft
W. Rodrigueza
,
C. Whitehead
,
+5 authors
C. Bisgaier
2012
Corpus ID: 72408979
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Bcl-2 and bcl-XL are anti-apoptotic proteins that…
Expand
2012
2012
Design of a phase I clinical trial with PNT2258, a novel DNA interference oligonucleotide (DNAi), in patients with advanced solid tumors.
D. Rasco
,
A. Tolcher
,
+8 authors
W. Rodrigueza
2012
Corpus ID: 91056539
TPS3110 Background: With the knowledge that Bcl-2 facilitates drug resistance and cell survival, a DNA interference (DNAi…
Expand
2012
2012
620 A Study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in Patients with Advanced Solid Tumors
D. Rasco
,
A. Patnaik
,
+7 authors
A. Tolcher
2012
Corpus ID: 76315860
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE